Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Express Scripts
Boehringer Ingelheim
AstraZeneca
Harvard Business School

Last Updated: August 15, 2022

Investigational Drug Information for Firibastat


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Firibastat?

Firibastat is an investigational drug.

There have been 5 clinical trials for Firibastat. The most recent clinical trial was a Phase 1 trial, which was initiated on August 5th 2021.

The most common disease conditions in clinical trials are Hypertension, Infarction, and Kidney Failure, Chronic. The leading clinical trial sponsors are Quantum Genomics SA, Quotient Sciences, and Eurofins Optimed.

There are three US patents protecting this investigational drug and forty-seven international patents.

Recent Clinical Trials for Firibastat
TitleSponsorPhase
Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)PRA Health SciencesPhase 3
Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)Quantum Genomics SAPhase 3
Firibastat in Treatment-resistant HypertensionQuantum Genomics SAPhase 3

See all Firibastat clinical trials

Clinical Trial Summary for Firibastat

Top disease conditions for Firibastat
Top clinical trial sponsors for Firibastat

See all Firibastat clinical trials

US Patents for Firibastat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Firibastat See Plans and Pricing Derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfonates) and compositions comprising the same Institute National de la Sante et de la Recherche Medicale (Inserm) (Paris Cedex, FR) See Plans and Pricing
Firibastat See Plans and Pricing Method for the preparation of (3S, 3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) QUANTUM GENOMICS (Paris, FR) See Plans and Pricing
Firibastat See Plans and Pricing Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) QUANTUM GENOMICS (Massy, FR) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Express Scripts
Boehringer Ingelheim
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.